3M VAC Veraflo Therapy applied on surgical patient

Start Smart with 3M™ Veraflo™ Therapy

Discover how negative pressure wound therapy with instillation​ can help promote healing for complex wounds.

REQUEST A DEMO

3M™ Veraflo™ Therapy can provide positive clinical outcomes over standard of care, including traditional NPWT, in various wound types.

A systematic review of comparative studies and meta-analysis evaluated the performance of Veraflo Therapy versus control in 13 studies and 720 patients in various wound types. Results of the analysis revealed Veraflo Therapy delivered significant advantage over standard of care, including traditional NPWT.

  • Calendar Icon
    >50% reduced length of therapy¹’²

    (9.88 days vs 21.8 days, p=0.02)

  • Speedometer Icon
    Ready for closure almost twice as fast

    (7.88 days vs 14.36 days, p=0.003)

  • Greater Than 2 Times Icon
    Wounds were 2.39 times more likely to close¹

    (p=0.01)

  • Arrow pointing downards Icon
    >30% Fewer surgical debridements¹’²

    (1.77 debridements vs 2.69, p=0.008)

  • Bacteria Icon
    Reduced bacterial count from baseline¹

    Odds were 4.4 times greater (p=0.003)


3M™ V.A.C. Veraflo Cleanse Choice™ Dressing with 3M™ Veraflo™ Therapy: Venous leg ulcer.

A 60-year-old female presented with a venous leg ulcer (10 cm x 16 cm x 1.5 cm) of the right distal lower extremity. Systemic antibiotics were initiated upon presentation.

  • Wound Before Veraflo Treatment

    Figure 1: Wound at presentation. A. Anterior view. B. Medial view.
     

    • Dwell time: 10 minutes
    • NPWT time: 1 hour at -125mmHg
    • Solution: 34mL of quarter-strength Dakin's® solution
  • Wound After Veraflo Treatment

    Figure 2: Wound after 24 hours of V.A.C. Veraflo Cleanse Choice Dressing with Veraflo Therapy. Solution changed to 28mL normal saline.

Patient data and photos courtesy of Elizabeth Faust, MSN, RN, CRNP, CWS, CWOCN-AP, Kersten Reider BSN, RN, CWOCN, Tower Health System, West Reading, PA NOTE: As with any case study, the results and outcomes should not be interpreted as a guarantee or warranty of similar results. Individual results may vary depending on the patient's circumstances and condition


What is Veraflo™ Therapy

A smart start to managing bioburden.

The number of microorganisms with which an object is contaminated is referred to as the bioburden.³

Bioburden formation is commonly considered to occur in five main stages.⁷

  • Chart showing the five main stages of Bioburden formation

Veraflo™ Therapy helps disrupt the bioburden cycle through repeated cleansing cycles.

  • Hands Washing Icon

    Cleanse

    Delivers topical wound solutions that dwell in the wound to help dilute and solubilize infectious material⁴

  • Bandages Icon

    Remove

    Removes solubilized wound debris and infectious materials, under negative pressure to help lower bioburden⁵

  • Heart & Medical Cross Icon

    Promote

    Promotes granulation tissue formation and perfusion to prepare the wound for closure⁶


3M™ V.A.C. Veraflo Cleanse Choice™ Dressing Video

Watch the mechanical movement at the wound bed.


Manage wounds with thick exudate such as slough and fibrin using 3M™ V.A.C. Veraflo Cleanse Choice™ Dressing

  • Veraflo Cleanse Choice Dressing

    Discover the wound cleansing option for when surgical debridement is not available. V.A.C. Veraflo Cleanse Choice™ Dressing facilitates the removal of thick exudate and infectious materials while promoting granulation tissue formation⁴.

    Learn More >

    Watch the video to see how it works >


Practice efficient medicine with a smarter way to manage wounds​

Wounds may be susceptible to contamination or the development of bioburden – key contributors to complications like infection, inflammation, and delayed healing. 3M™ Veraflo™ Therapy combines vacuum assisted drainage with automated topical wound solution distribution to consistently cleanse and remove wound debris helping to reduce bioburden.

Treatment of soft tissue defect from transfemoral amputation using  3M™ Veraflo™ Therapy

Following a boating injury, a 26-year-old female received transfemoral amputation that resulted in soft tissue defect measuring approximately 90x45cm². Antibiotics were administered throughout the patient treatment period. With patient critical condition and debridement no longer an option, Veraflo Therapy with V.A.C. Veraflo Cleanse Choice Dressing was initiated. Dwell time: 5 minutes NPWT time: 2 hours at -150mmHg Solution: 100mL Dankin's Solution.

Patient data and photos courtesy of Brandon Hill, RN, CWCN, FACCWS; Ochsner Louisiana State University Health Shreveport, Shreveport, LA
NOTE: As with any case study, the results and outcomes should not be interpreted as a guarantee or warranty of similar results. Individual results may vary depending on the patient’s circumstances and condition.


Use of 3M™ Veraflo™ Therapy can potentially reduce costs versus standard of care including NPWT

  • Improved wound outcomes can result in health economic benefits
  • An economic analysis of the Gabriel et al. meta-analysis¹ with non-standardized means² illustrates potential cost effectiveness for Veraflo Therapy
     

NOTE: The model uses select study data to provide an illustration of estimates of costs for use of Veraflo Therapy or Standard of Care (Control). This model is an illustration and not a guarantee of actual individual costs, savings, outcomes or results. The facility is advised to use this model as an illustration only to assist in an overall assessment of products and pricing

  • Veraflo Therapy Sample Health Economic Model Chart
  • NPWT Therapy Cost Chart

A. Granick MS, et al. Clinical and Economic Impact of Hydrosurgical Debridement on Chronic Wounds. Wounds Research. https://www.woundsresearch.com/article/5277. Published February 1, 2006.
Accessed December 11, 2020. B. Control costs vary widely. Average 3M™ V.A.C.® Therapy daily costs are used to be conservative. Daily Veraflo Therapy cost is an estimate only; individual facility cost may vary.
The model uses select study data to provide an illustration of estimates of costs for use of Veraflo Therapy or Standard of Care (Control). This model is an illustration and not a guarantee of actual individual costs,
savings, outcomes or results. The facility is advised to use this model as an illustration only to assist in an overall assessment of products and pricing.


Help improve clinical outcomes for various wound types including:

  • Pressure ulcer on foot
    Pressure Ulcers
  • Diabetic foot infection with ulceration
    Diabetic Wounds
  • Traumatic wound on ankle
    Traumatic Wounds
  • Surgical wound on leg
    Dehisced Wounds

3M™ Veraflo™ Therapy can be used to help promote wound healing in wounds with the following characteristics:
 

  • Clean wounds
  • Contaminated or chronically infected wounds that require cleansing​
  • Wounds with heavy bioburden​
  • Wounds that are difficult to granulate​
  • Adequately cleansed and debrided wounds

Experience seamless support for you and your patients​ that only 3M can provide

Make managing complex wounds a simple affair. From ordering to discharge, we offer education, training, bedside support, and product servicing so you can make the most of your 3M™ Veraflo™ Therapy system.

  • All fields are required unless indicated optional

  • 3M takes your privacy seriously. 3M and its authorized third parties will use the information you provided in accordance with our Privacy Policy to send you communications which may include promotions, product information and service offers. Please be aware that this information may be stored on a server located in the U.S. If you do not consent to this use of your personal information, please do not use this system.

  • Submit

Our apologies...

An error has occurred while submitting. Please try again later...

Thank you!

Your form was submitted successfully. A 3M representative will reach out to you soon.


Interested to learn more about 3M™ Veraflo™ Therapy?

From product demos, purchase inquiries to technical training, our team is here to help.


View patient results using​ 3M™ Veraflo™ Therapy

  • Download Veraflo Therapy patient case study brochure

    Explore clinical cases of Veraflo Therapy used across various wound types. Plus, view results from a recently published meta-analysis of 13 studies and 720 patients.


View all related products


  1. Gabriel, Allen MD, FACS; Camardo, Mark MS; O’Rorke, Erin BS; Gold, Rebecca BS; Kim, Paul J.DPM, MS, FACFAS Effects of Negative-Pressure Wound Therapy With Instillation versus Standard of Care in Multiple Wound Types: Systematic Literature Review and Meta-Analysis, Plastic and Reconstructive Surgery: January 2021 - Volume 147 - Issue1S-1 - p 68S-76S doi:10.1097/PRS.0000000000007614.
  2. Camardo, Mark. “Veraflo Meta-Analysis Standardized and Non-Standardized Means.”, 3M Internal Report, San Antonio,Texas, 2020.
  3. Bjarnsholt T, Eberlein T, Malone M, Schultz G. Management of wound biofilm made easy. London: Wounds International 2017; 8(2).
  4. Teot L, Boissiere F, Fluieraru S. Novel foam dressing using negative pressure wound therapy with instillation to remove thick exudate, Int Wound J .2017 Oct;14(5):842-848.
  5. Brinkert D, Mazen A, Naud M, Maire N, Trial C, Teot L. Negative pressure wound therapy with saline instillation: 131 patient case series. Int Wound J. 2013 Dec;10 Suppl1:56-60.
  6. Gupta S, Gabriel A, Lantis J, Teot L. Clinical recommendations and practical guide for negative pressure wound therapy with instillation. Int Wound J. 2016 Apr; 13(2):159-174.
  7. A fact a day – biofilms and wound care. Wound Source. 2018. Available at: https://pages.woundsource.com/woundsource-practice-accelerator-biofilms-and-wound-care/.
  8. Costerton JW, Stewart PS, Greenberg EP. Bacterial Biofilms: A Common Cause of Persistent Infection. Science. 1999; 284 (5418):1318-1322.
  9. Davies DG, Geesey GG. Regulation of the Alginate Biosynthesis Gene algC in Pseudomonas aeruginosa during Biofilm Development in Continuous Culture. Appl Environ Microbiol. 1995; 61(3):860-867.
  10. Cicmanec F, Holder IA. Growth of Pseudomonas aeruginosa in Normal and Burned Skin Extract: Role of Extracellular Proteases. Infect Immun. 1979; 25(2):477-483.
  11. Harrison-Balestra C, Cazzaniga BS, Davis SC, et al. A Wound-Isolated Pseudomonas aeruginosa Grows a Biofilm In Vitro Within 10 Hours and Is Visualized by Light Microscopy. Dermatol Surg. 2003: 29(6):631-635.
  12. Schaber JA, Triffo WJ, Suh SJ, et al. Pseudomonas aeruginosa Forms Biofilms in Acute Infection Independent of Cell-to-Cell Signaling. Infect Immun. 2007; 75 (8):3715-3721.
  13. Wolcott RD, Rumbaugh KP, James G, et al. Biofilm maturity studies indicate sharp debridement opens a time-dependent therapeutic window. J Wound Care. 2010; 19 (8):320-328.